Edition:
United Kingdom

Bergenbio ASA (BGBIO.OL)

BGBIO.OL on Oslo Stock Exchange

13.10NOK
25 Jun 2019
Change (% chg)

-- (--)
Prev Close
kr13.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
61,390
52-wk High
kr43.40
52-wk Low
kr12.38

Latest Key Developments (Source: Significant Developments)

Bergenbio Presents Preliminary Phase II Clinical Data At EHA 24
Friday, 14 Jun 2019 

June 14 (Reuters) - Bergenbio ASA ::BERGENBIO PRESENTS PRELIMINARY PHASE II CLINICAL DATA AT EHA 24: BEMCENTINIB IN COMBINATION WITH LOW DOSE CHEMOTHERAPY YIELDS DURABLE RESPONSES IN AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY.PRELIMINARY RESPONSES REPORTED IN 6/14 (43%) PATIENTS, WITH CR/CRI IN 4/14 (29%) PATIENTS.PRELIMINARY RESPONSES SUBSTANTIALLY HIGHER THAN PREVIOUSLY OBSERVED/HISTORICAL BENCHMARKS IN SINGLE-AGENT CYTARABINE (LOW-DOSE CHEMOTHERAPY).MEDIAN RELAPSE-FREE SURVIVAL 7.9 MONTHS IN CR/CRI PATIENTS (DATA NOT MATURE).COMBINATION TREATMENT OF BEMCENTINIB AND LDAC WAS OVERALL WELL-TOLERATED.MOST COMMON ADVERSE EVENTS ( >15% OF PATIENTS) INCLUDED ANAEMIA, NEUTROPENIA AND DIARRHOEA.SECOND BIOMARKER POSTER SHOWS PHARMACODYNAMIC EFFECTS OF BEMCENTINIB ON AML PATIENTS BLAST CELL SIGNAL AT JUST 4 HOURS POST-DOSING OF BEMCENTINIB.  Full Article

Bergenbio ASA Says Successfully Completed Private Placement
Thursday, 13 Jun 2019 

June 13 (Reuters) - Bergenbio ASA ::BERGENBIO ASA - SUCCESSFULLY COMPLETED PRIVATE PLACEMENT.BERGENBIO ASA - RAISED GROSS PROCEEDS OF NOK 74,184,444 THROUGH ALLOCATION OF 5,495,144 NEW SHARES ON SUCCESSFUL COMPLETION OF PRIVATE PLACEMENT.BERGENBIO ASA - RAISED GROSS PROCEEDS OF NOK 74,184,444 THROUGH ALLOCATION OF 5,495,144 NEW SHARES AT A SUBSCRIPTION PRICE OF NOK 13.50 PER SHARE.  Full Article

Bergenbio Considers Private Placement
Thursday, 13 Jun 2019 

June 13 (Reuters) - Bergenbio ASA ::: CONTEMPLATED PRIVATE PLACEMENT.TO USE PROCEEDS FROM PRIVATE PLACEMENT TO CONTINUE ADVANCING CLINICAL PROGRAMS WITH BEMCENTINIB IN ACUTE MYELOID LEUKAEMIA.SUBSCRIPTION PRICE IN PRIVATE PLACEMENT WILL BE NOK 13.50 PER OFFER SHARE.MINIMUM SUBSCRIPTION AND ALLOCATION AMOUNT IN PRIVATE PLACEMENT WILL BE NOK EQUIVALENT OF EUR 100,000.ARCTIC SECURITIES AS (ON BEHALF OF MANAGERS) HAS ENTERED INTO A SHARE LENDING AGREEMENT WITH METEVA AS.  Full Article

Bergenbio Presents New Preliminary Clinical In Phase II Trial With Bemcentinib And Keytruda
Sunday, 2 Jun 2019 

June 2 (Reuters) - Bergenbio ASA ::BERGENBIO PRESENTS NEW PRELIMINARY CLINICAL AND BIOMARKER DATA SHOWING DURABLE RESPONSE & MEDIAN SURVIVAL RATES IN PHASE II TRIAL WITH BEMCENTINIB AND KEYTRUDA IN PTS WITH ADVANCED NSCLC AT ASCO 2019.BERGENBIO- PROMISING CLINICAL ACTIVITY CONTINUES TO BE SEEN, PARTICULARLY IN PATIENTS WITH AXL POSITIVE TUMOURS INCLUDING THOSE WITH LOW OR NO PD-L1 EXPRESSION.  Full Article

Bergenbio: Grant From Research Council Of Norway Under BIA Programme
Monday, 4 Feb 2019 

Feb 4 (Reuters) - Bergenbio ASA ::BERGENBIO ANNOUNCES THE ALLOCATION OF RESEARCH AND DEVELOPMENT GRANT OF UP TO NOK 12M AWARDED.AWARD OF A GRANT FROM RESEARCH COUNCIL OF NORWAY UNDER USER-DRIVEN INNOVATION AREA (BIA) PROGRAMME..PROCEEDS WILL BE USED TO FUND RESEARCH INTO AXL'S ROLE IN FIBROTIC DISEASES.UP TO NOK 12 MILLION WILL BE DISBURSED OVER A THREE-YEAR PERIOD STARTING IN 2019.  Full Article

Bergenbio Announces Start Of Phase I Trial Evaluating BGB149
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Bergenbio ASA ::BERGENBIO ANNOUNCES START OF PHASE I TRIAL EVALUATING FIRST-IN-CLASS.PHASE I STUDY WILL INVESTIGATE SAFETY AND PHARMACOKINETICS IN HEALTHY VOLUNTEERS.BERGENBIO - EXPECTS RESULTS FROM PHASE I TRIAL IN 2019, TO ANNOUNCING BGB149'S FURTHER CLINICAL DEVELOPMENT STRATEGY IN COMING MONTHS.ANNOUNCES START OF PHASE I TRIAL EVALUATING FIRST-IN-CLASS ANTI-AXL ANTIBODY BGB149.  Full Article

Bergenbio Q3 Net Loss Widens To NOK 37.7 Million
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Bergenbio ASA ::: RESULTS FOR THE THIRD QUARTER 2018.TOTAL OPERATING EXPENSES FOR Q3 WERE NOK 38.1 MILLION (NOK 36.6 MILLION).Q3 NET LOSS NOK 37.7 MILLION VERSUS LOSS NOK 35.4 MILLION YEAR AGO.  Full Article

BerGenBio Q2 Net Loss Widens To NOK 49.2 Million
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - BerGenBio ASA ::Q2 OPERATING LOSS NOK 50.7 MILLION VERSUS LOSS NOK 33.8 MILLION YEAR AGO.Q2 NET LOSS NOK 49.2 MILLION VERSUS LOSS NOK 34.1 MILLION YEAR AGO.  Full Article

Bergenbio Q1 Operating Loss Narrows To NOK 54.8 Million
Tuesday, 15 May 2018 

May 15 (Reuters) - Bergenbio ASA ::Q1 OPERATING LOSS NOK 54.8 MILLION VERSUS LOSS NOK 65.8 MILLION YEAR AGO.Q1 NET LOSS NOK 53.8 MILLION VERSUS LOSS NOK 65.1 MILLION YEAR AGO.  Full Article

BerGenBio: Promising Data Highlighting Selective AXL Inhibitor
Wednesday, 18 Apr 2018 

April 18 (Reuters) - BERGENBIO ASA ::BERGENBIO: PROMISING DATA HIGHLIGHTING SELECTIVE AXL INHIBITOR.DATA HIGHLIGHT BEMCENTINIB'S POTENTIAL TO REVERSE TUMOUR IMMUNE SUPPRESSION AND ENHANCE IMMUNE CHECKPOINT INHIBITOR EFFICACY.  Full Article